Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Total Debt (2021 - 2025)

Arcutis Biotherapeutics has reported Total Debt over the past 5 years, most recently at $109.0 million for Q4 2025.

  • Quarterly results put Total Debt at $109.0 million for Q4 2025, up 1.64% from a year ago — trailing twelve months through Dec 2025 was $109.0 million (up 1.64% YoY), and the annual figure for FY2025 was $109.0 million, up 1.64%.
  • Total Debt for Q4 2025 was $109.0 million at Arcutis Biotherapeutics, roughly flat from $108.5 million in the prior quarter.
  • Over the last five years, Total Debt for ARQT hit a ceiling of $204.6 million in Q3 2024 and a floor of $72.4 million in Q4 2021.
  • Median Total Debt over the past 5 years was $196.8 million (2022), compared with a mean of $150.9 million.
  • Biggest five-year swings in Total Debt: soared 173.35% in 2022 and later tumbled 46.98% in 2025.
  • Arcutis Biotherapeutics' Total Debt stood at $72.4 million in 2021, then soared by 173.35% to $197.8 million in 2022, then grew by 2.04% to $201.8 million in 2023, then crashed by 46.88% to $107.2 million in 2024, then grew by 1.64% to $109.0 million in 2025.
  • The last three reported values for Total Debt were $109.0 million (Q4 2025), $108.5 million (Q3 2025), and $108.0 million (Q2 2025) per Business Quant data.